Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 4;100(14):688.
doi: 10.1212/WNL.0000000000207210.

Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Brendan Jen-Wei Tan  1 , Ling-Ling Chan  1 , Eng-King Tan  1
Affiliations
Comment

Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Brendan Jen-Wei Tan et al. Neurology. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ursu R, Maillet D, Belin C, et al. Long-term neurologic safety in patients with B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. Neurology. 2022;99(12):511-515. doi: 10.1212/WNL.0000000000201083. - DOI - PubMed
    1. Shalabi H, Wolters PL, Martin S, et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. J Immunother. 2018;41(7):350-358. doi: 10.1097/CJI.0000000000000241. - DOI - PMC - PubMed
    1. Maillet D, Belin C, Moroni C, et al. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro Oncol. 2021;23(9):1569-1575. doi: 10.1093/neuonc/noab077. - DOI - PMC - PubMed

MeSH terms